Josh Riggs
President & CEO, OncoSight
Replay available
Oncocyte Corporation (OCX) Q4 2024 Earnings Call
Oncocyte Corporation (NASDAQ: OCX) Q4 2024 earnings conference call, held 2025-03-25. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Andrea James
Chief Financial Officer, OncoSight
Eki Schutz
Chief Science Officer, OncoSight
Mark Mazzaro
Analyst, BTIG
Mike Mattson
Analyst, Needham
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Insight Molecular Diagnostics Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.857 You have joined the meeting as an attendee and will be muted throughout the meeting. 00:00:05.857 -- 00:00:10.702 Welcome, everyone, and thank you for joining us to discuss Oncocyte's fourth quarter 00:00:10.702 -- 00:00:13.322 2024 results. 00:00:13.444 -- 00:00:20.211 If you have not seen today's shareholder letter, please visit Oncocyte 00:00:20.211 -- 00:00:23.512 investor relations page at investors.oncocyte.com. 00:00:24.375 -- 00:00:30.153 Today's prepared remarks build upon the information already shared in this robust letter. 00:00:30.153 -- 00:00:35.299 Joining us today are OncoSight President and CEO, Josh Riggs, Chief 00:00:35.299 -- 00:00:40.566 Science Officer, Eki Schutz, and CFO, Andrea James. 00:00:40.566 -- 00:00:44.250 We also have our analysts with us as panelists. 00:00:44.250 -- 00:00:48.816 After our prepared remarks, our analysts may ask questions. 00:00:48.816 -- 00:00:52.501 Attendees may also type questions into the Q&A. 00:00:52.501 -- 00:00:58.250 Before turning the call over to Josh Riggs, I'd like to go over our safe harbor. 00:00:58.250 -- 00:01:04.178 The company will make projections and forward-looking statements regarding future events. 00:01:04.178 -- 00:01:09.224 Any statements that are not historical facts are forward-looking statements. 00:01:09.224 -- 00:01:14.971 These statements are made pursuant to and within the meaning of the safe harbor provision 00:01:14.971 -- 00:01:19.595 of the Private Securities Litigation Reform Act of 1995. 00:01:19.677 -- 00:01:24.704 We encourage you to review the company's SEC filings, including the company's 00:01:24.704 -- 00:01:30.275 most recent form, 10-K, in subsequent forms 10Q, which identify 00:01:30.275 -- 00:01:35.681 risks and uncertainties that m...